BCAB News and Press, BioAtla Inc. From 06/09/22

Gainers: Rent the Runway (RENT) +10%. BioAtla (BCAB) +9%. Adaptive Biotechnologies Corporation (ADPT) +5%. Accolade (ACCD) +5%. Nurix Therapeutics (NRIX) +5%. Losers: DocuSign (DOCU) -23%. Stitch Fix (SFIX) -16%. Comtech Telecommunications  (CMTL) -15%. View (VIEW) -12%. DBV Te...

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short, Ph.D., Chair...

BioAtla, Inc. (BCAB) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors Jay Short - Chairman, CEO and Co-Founder Scott Smith - President Philippe Martin - Chief of Clinical Development and Operations Sheri Lydick - Senior Vice Presiden...

BioAtla (NASDAQ:BCAB) has recorded its worst intraday performance on Thursday after the clinical-stage biotech announced interim data from a Phase 2 trial that prompted Credit Suisse to downgrade the stock to Neutral from Outperform. Updated data generated from patients with soft tissue ...

Gainers: AxoGen (AXGN) +26%. Better Therapeutics (BTTX) +15%. Intercept Pharmaceuticals (ICPT) +13%. XORTX Therapeutics (XRTX)  +13%. Belite Bio (BLTE) +8%. Losers: Nephros (NEPH) -32%. BioAtla (BCAB) -27%. Outset Medical (OM) -10%. ...

The following slide deck was published by BioAtla, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: BioAtla, Inc. 2022 Q1 - Results - Earnings Call Presentation

– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma – – Mecbotamab vedotin (BA3011) Phase 2 interim analysis in NSCLC anticipated in first half 2022; interim update projected on 2Q22 earnings call &...

SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and other protein therapeutics, today announced that it plans to host a conference call and we...

BioAtla press release (NASDAQ:BCAB): Q4 Net loss was $23.4M compared to a net loss of $16.4M for the same quarter in 2020. Cash and cash equivalents as of December 31, 2021 were $245M. For further details see: BioAtla reports Q4 results

BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS - Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim update expected in first quarter results conference call. NSCLC Phase 2 interim update expected in first half 2022. - Ozuriftamab vedotin (BA3...